Radiotheranostics: a roadmap for future development
Ken Herrmann,Markus Schwaiger,Jason S. Lewis,Stephen B. Solomon,Barbara J. McNeil,Michael Baumann,Sanjiv S. Gambhir,Hedvig Hricak,Ralph Weissleder +8 more
TLDR
This Review aims to alert practitioners to the value of radiotheranostics and to outline a roadmap for future development.Abstract:
Radiotheranostics, injectable radiopharmaceuticals with antitumour effects, have seen rapid development over the past decade. Although some formulations are already approved for human use, more radiopharmaceuticals will enter clinical practice in the next 5 years, potentially introducing new therapeutic choices for patients. Despite these advances, several challenges remain, including logistics, supply chain, regulatory issues, and education and training. By highlighting active developments in the field, this Review aims to alert practitioners to the value of radiotheranostics and to outline a roadmap for future development. Multidisciplinary approaches in clinical trial design and therapeutic administration will become essential to the continued progress of this evolving therapeutic approach.read more
Citations
More filters
Journal ArticleDOI
The Future of Nuclear Medicine, Molecular Imaging, and Theranostics.
Wolfgang A. Weber,Johannes Czernin,Carolyn J. Anderson,Ramsey D. Badawi,Henryk Barthel,Frank M. Bengel,Lisa Bodei,Irene Buvat,Marcelo F. DiCarli,Michael M. Graham,Jan Grimm,Jan Grimm,Ken Herrmann,Lale Kostakoglu,Jason S. Lewis,Jason S. Lewis,David A. Mankoff,Todd E. Peterson,Heinrich R. Schelbert,Heiko Schöder,Barry A. Siegel,H. William Strauss +21 more
TL;DR: This work presents a meta-analyses of the proton-probes of positron-proton radiolysis and its implications for medicine, which have implications for drug discovery, treatment, and research into new materials and materials science and engineering.
Journal ArticleDOI
Cyclotron-based production of 68Ga, [68Ga]GaCl3, and [68Ga]Ga-PSMA-11 from a liquid target
Melissa E. Rodnick,Carina Sollert,Daniela Stark,Mara Clark,Andrew Katsifis,Brian G. Hockley,D. Christian Parr,Jens Frigell,Bradford D. Henderson,Monica Abghari-Gerst,Morand Piert,Michael J. Fulham,Stefan Eberl,Katherine Gagnon,Peter Scott +14 more
TL;DR: Direct cyclotron irradiation of a liquid target provides clinically relevant quantities of [ 68 Ga]Ga-PSMA-11 and is a viable alternative to traditional 68 Ge/ 68 Ga generators.
Journal ArticleDOI
Radiotheranostics in oncology: current challenges and emerging opportunities
TL;DR: The clinical experience with established radiotheranostics as well as novel areas of research and various barriers to progress are described, which summarize the current challenges and opportunities in this rapidly emerging area.
Journal ArticleDOI
PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports
Maike J. M. Uijen,Yvonne H.W. Derks,R I J Merkx,Melline G.M. Schilham,Joey Roosen,Bastiaan M. Privé,S van Lith,C.M.L. van Herpen,Martin Gotthardt,Sandra Heskamp,W A M van Gemert,James Nagarajah +11 more
TL;DR: In this paper, the authors describe the current knowledge of PSMA expression in other solid cancers and define a perspective towards broader clinical implementation of prostate-specific membrane antigen (PSMA)-RLT.
Journal ArticleDOI
Engineering in Medicine To Address the Challenge of Cancer Drug Resistance: From Micro- and Nanotechnologies to Computational and Mathematical Modeling.
Morgan Craig,Adrianne L. Jenner,Bumseok Namgung,Bumseok Namgung,Luke P. Lee,Luke P. Lee,Aaron Goldman,Aaron Goldman +7 more
TL;DR: This review explores the developing, complex, and under-recognized role of engineering in medicine to address the multitude of challenges in cancer drug resistance and suggests the proliferation of multidisciplinary science that embraces engineering.
References
More filters
Journal ArticleDOI
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Chris Parker,Sten Nilsson,Sten Nilsson,D. Heinrich,Svein Inge Helle,Joe M. O'Sullivan,Sophie D. Fosså,Ales Chodacki,Paweł Wiechno,John P Logue,Mihalj Seke,Anders Widmark,D. C. Johannessen,Peter Hoskin,David Bottomley,Nicholas D. James,Arne Solberg,Isabel Syndikus,Ján Kliment,S. Wedel,S. Boehmer,Marcos F. Dall'Oglio,Lars Franzén,Robert E. Coleman,Nicholas J. Vogelzang,C.G. O'Bryan-Tear,K. Staudacher,J. Garcia-Vargas,M. Shan,Øyvind S. Bruland,Oliver Sartor +30 more
TL;DR: In this study, which was terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival and was associated with low myelosuppression rates and fewer adverse events.
Journal ArticleDOI
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
Jonathan R. Strosberg,Ghassan El-Haddad,Edward M. Wolin,Andrew Eugene Hendifar,James C. Yao,Beth Chasen,Erik Mittra,Pamela L. Kunz,Matthew H. Kulke,Heather A. Jacene,David L. Bushnell,Thomas M. O'Dorisio,Richard A. Baum,Harshad R. Kulkarni,Martyn Caplin,Rachida Lebtahi,Timothy J. Hobday,Ebrahim S. Delpassand,E. Van Cutsem,Al B. Benson,Raj Srirajaskanthan,Marianne Pavel,J. Mora,Jordan Berlin,Enrique Grande,N. Reed,Ettore Seregni,Kjell Öberg,M. Lopera Sierra,P. Santoro,Thomas Thevenet,Jack L. Erion,Philippe Ruszniewski,Dirk Jan Kwekkeboom,E.P. Krenning +34 more
TL;DR: Treatment with lutetium‐177 (177Lu)–Dotatate resulted in markedly longer progression‐free survival and a significantly higher response rate than high‐dose octreotide LAR among patients with advanced midgut neuroendocrine tumors.
Journal ArticleDOI
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
Martin A. Cheever,Martin A. Cheever,James P. Allison,Andrea S. Ferris,Olivera J. Finn,Benjamin M. Hastings,Toby T. Hecht,Ira Mellman,Sheila A. Prindiville,Jaye L. Viner,Louis M. Weiner,Lynn M. Matrisian +11 more
TL;DR: The findings reflect the current status of the cancer vaccine field, highlight the possibility that additional organized efforts and funding would accelerate the development of therapeutically effective cancer vaccines, and accentuate the need for prioritization.
Journal ArticleDOI
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
Thomas E. Witzig,Leo I. Gordon,Fernando Cabanillas,Myron S. Czuczman,Christos Emmanouilides,Robin Joyce,Brad Pohlman,Nancy L. Bartlett,Gregory A. Wiseman,Norman Padre,Antonio J. Grillo-Lopez,Pratik S. Multani,Christine A. White +12 more
TL;DR: Radioimmunotherapy with (90)Y ibritumomab tiuxetan is well tolerated and produces statistically and clinically significant higher ORR and CR compared with rituximab alone.
Journal ArticleDOI
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
Michael S Hofman,Michael S Hofman,John Violet,Rodney J. Hicks,Rodney J. Hicks,Justin Ferdinandus,Sue Ping Thang,Tim Akhurst,Tim Akhurst,Amir Iravani,Grace Kong,Aravind S. Ravi Kumar,Declan G. Murphy,Declan G. Murphy,Peter Eu,Price Jackson,Mark Scalzo,Scott Williams,Shahneen Sandhu,Shahneen Sandhu +19 more
TL;DR: The findings show that radionuclide treatment with Lutetium-177 [177Lu]-PSMA-617 has high response rates, low toxic effects, and reduction of pain in men with metastatic castration-resistant prostate cancer who have progressed after conventional treatments.
Related Papers (5)
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
Jonathan R. Strosberg,Ghassan El-Haddad,Edward M. Wolin,Andrew Eugene Hendifar,James C. Yao,Beth Chasen,Erik Mittra,Pamela L. Kunz,Matthew H. Kulke,Heather A. Jacene,David L. Bushnell,Thomas M. O'Dorisio,Richard A. Baum,Harshad R. Kulkarni,Martyn Caplin,Rachida Lebtahi,Timothy J. Hobday,Ebrahim S. Delpassand,E. Van Cutsem,Al B. Benson,Raj Srirajaskanthan,Marianne Pavel,J. Mora,Jordan Berlin,Enrique Grande,N. Reed,Ettore Seregni,Kjell Öberg,M. Lopera Sierra,P. Santoro,Thomas Thevenet,Jack L. Erion,Philippe Ruszniewski,Dirk Jan Kwekkeboom,E.P. Krenning +34 more
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
Michael S Hofman,Michael S Hofman,John Violet,Rodney J. Hicks,Rodney J. Hicks,Justin Ferdinandus,Sue Ping Thang,Tim Akhurst,Tim Akhurst,Amir Iravani,Grace Kong,Aravind S. Ravi Kumar,Declan G. Murphy,Declan G. Murphy,Peter Eu,Price Jackson,Mark Scalzo,Scott Williams,Shahneen Sandhu,Shahneen Sandhu +19 more
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
Michael S Hofman,Michael S Hofman,Nathan Lawrentschuk,Roslyn J. Francis,Roslyn J. Francis,Colin Tang,Ian Vela,Paul Thomas,Paul Thomas,Natalie Rutherford,Jarad Martin,Mark Frydenberg,Ramdave Shakher,Lih-Ming Wong,Kim Taubman,Sze Ting Lee,Edward Hsiao,Paul Roach,Michelle K. Nottage,Ian Kirkwood,Ian Kirkwood,Dickon Hayne,Emma Link,Emma Link,Petra Marusic,Anetta Matera,Alan Herschtal,Amir Iravani,Amir Iravani,Rodney J. Hicks,Rodney J. Hicks,Scott Williams,Scott Williams,Declan G. Murphy,Declan G. Murphy +34 more